Marshal your PROs for market access
This article was originally published in Scrip
Executive Summary
Patient reported outcomes (PROs), with their ability to reflect patients' experience of a drug's impact on symptoms or overall quality of life (QoL), are increasingly valued by the regulators and health technology assessment (HTA) bodies. However, manufacturers need to ensure the PROs they capture satisfy the regulators' and HTAs' standards and requirements in order to have an impact.